Key result
Peritoneal dialysis linked to ~75% NYHA class regression in refractory CHF and Stage IV CKD.
Why the study?
Peritoneal dialysis has been reported as a long-term maintenance treatment of refractory congestive heart failure, prompting evaluation of outcomes in patients with concurrent Stage IV chronic kidney disease.
Does peritoneal dialysis improve clinical outcomes in patients with refractory congestive heart failure and Stage IV chronic kidney disease?
Observational (n=24)
No
Does peritoneal dialysis improve clinical outcomes in patients with refractory congestive heart failure and Stage IV chronic kidney disease?
Peritoneal dialysis may be a safe and effective adjunctive treatment for improving symptoms and reducing hospitalizations in patients with refractory congestive heart failure and advanced chronic kidney disease.
Should not yet change practice in refractory heart failure; leaves open a potential adjunctive role pending randomized trials.
Peritoneal dialysis (PD) has been reported as a long-term maintenance treatment of refractory congestive heart failure (RCHF). In this study, we aimed to evaluate the outcome of 24 PD patients with RCHF and Stage IV chronic kidney disease. The continuous ambulatory PD program consisted of two or three exchanges daily and one exchange nightly. In the follow-up period, clinical and echocardiographic biochemical findings and the need for hospitalization were recorded. Fifteen patients (66.7%) were male, and the mean age was 62.75 years. Under the PD treatment, the average daily urine volume and ultrafiltration of the patients were 800-1000 mL and 1000-15,000 mL, respectively. Ten patients were followed for 24 months and eight patients were followed for 12 months. During the follow-up period, there was a regression in the New York Heart Association heart failure class (from Class IV to Class II in 18 patients), and a decrease in body weights and an increase in serum sodium levels in all patients. Only two patients were hospitalized for cardiovascular disease over 2 years. During the follow-up period, one patient was transferred to hemodialysis because of peritonitis. In conclusion, in patients with RCHF and chronic renal failure without dialysis, PD in addition to standard treatment may be a safe treatment choice.
No takes yet. Share an insight, caveat, or question.
Altun et al. (2025) conducted an observational in Refractory congestive heart failure and Stage IV chronic kidney disease (n=24). Peritoneal dialysis was evaluated on Regression in New York Heart Association heart failure class (from Class IV to Class II). Peritoneal dialysis in patients with refractory congestive heart failure and Stage IV chronic kidney disease led to NYHA class regression in 75% of patients and only 2 hospitalizations over 2 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: